Press Release

Nevro Corp Closes $58 Million in New Financing

Nevro Corp., a neuromodulation company focused on relief of chronic
pain, announced today that it has completed a $58 million financing
round led by new investor, Johnson & Johnson Development Corporation
(JJDC). Existing investors participating in this financing round
included Aberdare Ventures, Accuitive Medical Ventures, Bay City
Capital, Mayo Clinic, MPM Capital, and Three Arch Partners.

The funds will be used to sponsor a pivotal clinical study in the U.S.
and provide continued support for the company’s international
commercialization strategy.

“We are excited to add JJDC to our experienced team of investors,” said
Michael DeMane, chief executive officer of Nevro Corp. “This round of
financing will underpin our expansion in global markets and fund U.S.
clinical development efforts for this next generation neuromodulation
technology. There is a significant need for better outcomes, a simpler
procedure, and an enhanced patient experience in the treatment for
chronic pain. We hope to address these needs.”

About Nevro Corp

Nevro Corp., headquartered in Menlo Park, California, is a
privately-held medical device company founded in 2007 to provide
advances in chronic pain relief through neuromodulation technology. The
Nevro Spinal Cord Stimulation System received CE mark in 2010 and is now
commercially available at leading centers outside the United States. For
more information, please visit www.nevro.com.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.